INDUSTRY STAKEHOLDERS HAVE MADE SIGNIFICANT INVESTMENTS TOWARDS THE DEVELOPMENT OF ORALLY ADMINISTERED PROTEIN AND PEPTIDE THERAPEUTICS Over the years, advances in recombinant DNA technology and ex vivo synthesis of biomolecules have led to the development and (in some cases) approval of several protein / peptide-based therapeutics. Considering the therapeutic advantages associated with proteins